Arteriovenous Fistula Treatment Market: By Treatment (Drugs, Transcatheter Embolization, Ultrasound-guided Compression, Surgery), By Type (Arteriovenous Fistulas, Dural, Peripheral, Pial or Cerebral, Other Fistula Types), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Arteriovenous Fistula Treatment Market Size was valued at USD 346.7 million in 2022 and is poised to grow at a CAGR of 6.46% over 2023-2029. An arteriovenous fistula is an abnormal connection or passageway between an artery and a vein that may be congenital, surgically created for hemodialysis treatments, or acquired due to a pathological process, such as trauma or erosion of an aortic aneurysm. Based on the treatment type, Transcatheter embolization is anticipated to dominate the market share over the forecast period. According to the American Heart Association, the crude incidence rates between 2009 and 2019 were 2.040 per 1,00,000 person-years for all arteriovenous fistulas. The growing awareness and development of new treatment methods will act as the growth drivers for the market, whereas the lack of awareness regarding arteriovenous fistula treatment might have a negative impact on the market. The limited treatment methods and the highly affected population due to the disease are huge opportunities for the growth of the market.

Arteriovenous Fistula Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

6.4%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Arteriovenous Fistula Treatment Market Dynamics

The arteriovenous fistula treatment market is expected to expand as key players in the market are investing largely in new treatment methods such as photodynamic therapy, antiangiogenic therapy, and other sclerotherapy methods. Furthermore, there have been growing FDA approvals for noninvasive devices for arteriovenous fistula creation. Thus, the growing geriatric population, increasing prevalence of end-stage renal disease, favorable reimbursement policies, and rising healthcare expenditure will drive the arteriovenous fistula treatment market growth over the forecast period.

Key Features of the Reports

  • The arteriovenous fistula treatment market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Arteriovenous Fistula Treatment Market Segmentation

By Treatment Type
  • Drugs
  • Transcatheter Embolization
  • Ultrasound-guided Compression
  • Surgery
By Type
  • Arteriovenous Fistulas
  • Dural
  • Peripheral
  • Pial or Cerebral
  • Other Fistula Types
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA
  • Rest of MEA

Frequently Asked Questions

The Arteriovenous Fistula Treatment market was valued at USD 346.7 million in 2022 and is expected to grow at a 6.46% CAGR over the forecast period 2023 – 2029.

The limited treatment methods and the highly affected population due to the disease are the key opportunities for the Arteriovenous Fistula Treatment market.

The growing awareness and development of new treatment methods are the growth drivers in the Arteriovenous Fistula Treatment market.

Becton Dickinson, Medtronic, Cook Medical, Teleflex Incorporated, Fresenius Medical Care AG & Co. KGaA, NxStage Medical, Poly Medicure Limited, and Braun Melsungen AG are a few companies operating in the Arteriovenous Fistula Treatment market.

  • Becton Dickinson
  • Medtronic
  • Cook Medical
  • Teleflex Incorporated
  • Fresenius Medical Care AG & Co. KGaA
  • NxStage Medical
  • Poly Medicure Limited
  • Braun Melsungen AG